Discord prevails over pt privacy in clinical trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 8
Volume 18
Issue 8

Cancer researchers and compliance officials agree that patients enrolled in clinical trials are entitled to a high level of privacy protection, but there is significant tension between the two groups over how HIPAA rules should be implemented, according to the results of a survey by the ASCO Cancer Research Committee.

Cancer researchers and compliance officials agree that patients enrolled in clinical trials are entitled to a high level of privacy protection, but there is significant tension between the two groups over how HIPAA rules should be implemented, according to the results of a survey by the ASCO Cancer Research Committee.

Elizabeth Goss, JD, and colleagues, led the study in which 27 individuals (13 investigators and 14 compliance officials) from 13 institutions were asked to describe the anticipated approach of their institutions to HIPAA privacy rule compliance in three hypothetical research studies: a genetics study, a survivorship study, and a research study.

The research study scenario, which involved biospecimens and data repositories, was the most prominent source of disagreement, according to the results. "The disagreements are seen most clearly with regard to the appropriate definition of a ‘future research use' of protected health information in biospecimen and data repositories and the standards for a waiver of authorization for disclosure and use of such data," the authors wrote. Compliance officials and IRB members voiced concerns about the protection of large repositories of data and called for such actions as patient reconsent and reauthorization. Investigators said that a cautious attitude could slow down or even block research endeavors (J Clin Oncol online, July 27, 2009).

In response, ASCO proposed the development of best practices documents to guide creation of data repositories, disclosure and use of data from such repositories, and the design of survivorship and genetics studies. Such guidelines should ease the burden of delayed or abandoned trials, they stated.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts in this video
2 experts in this video
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
2 experts are featured in this series.
Related Content